The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

James P. Allison, PhD, discusses the development of ipilimumab.

James P. Allison, PhD, discusses his early career at The University of Texas MD Anderson Cancer Center.

James P. Allison, PhD, discusses his research on reverse translation in cancer. 

The combination of enasidenib plus azacitidine was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia.

Daniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

Significant progress with rapidly evolving therapies, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, has been made to extend the median overall survival and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

John V. Heymach, MD, PhD, discusses the background of the Impower010 trial, the benefit for patients with PD-L1 levels of at least 1%, and the exciting direction adjuvant therapy in NSCLC is heading.

Sequential radiotherapy demonstrated preliminary efficacy and safety as a potential alternative to systemic therapy in patients with oligometastatic renal cell carcinoma.

The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

The phase 1/2 MANIFEST and phase 3 MANIFEST-2 trials are examining a complement to JAK inhibition that could improve responses and disease management up front in patients with myelofibrosis.